Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > PR ideas

<< Previous

Bullboard Posts

Next >>

Comment by Wino115on Apr 12, 2021 2:39pm

92 Views

Post# 32978714

RE:PR ideas

Someone a month or so ago did just that on a number of stock subreddits (CanadianInvestor and Biotechinvestor are two I recall). I haven't seen him post here in a while so he's gone quiet. But he did a good job there and saw interest. It's probably worth a follow-up post of an update on this new data and whatever comes in the quarterly conference call this week to keep the flow going.